NCT02151409 - Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

InflammationSystemic Lupus ErythematosusRheumatoid ArthritisHealthy

Interventions

DRUG

NNC 0151-0000-0000

A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.

DRUG

NNC 0151-0000-0000

A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels

DRUG

placebo

A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).

Trial Locations (1)

Novo Nordisk Investigational Site, Groningen